[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO932391L - Angiotensin-II-reseptorantagonister for behandling av hjerterytmeforstyrrelser - Google Patents

Angiotensin-II-reseptorantagonister for behandling av hjerterytmeforstyrrelser

Info

Publication number
NO932391L
NO932391L NO932391A NO932391A NO932391L NO 932391 L NO932391 L NO 932391L NO 932391 A NO932391 A NO 932391A NO 932391 A NO932391 A NO 932391A NO 932391 L NO932391 L NO 932391L
Authority
NO
Norway
Prior art keywords
angiotensin
cardiac arrhythmias
treatment
receptor antagonists
several meanings
Prior art date
Application number
NO932391A
Other languages
English (en)
Other versions
NO932391D0 (no
Inventor
Holger Heitsch
Wolfgang Linz
Adalbert Wagner
Heinz-Werner Kleemann
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO932391D0 publication Critical patent/NO932391D0/no
Publication of NO932391L publication Critical patent/NO932391L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet antagonister for angiotensin-II-reseptorer av AT-undertypen som kan anvendes for bekjempelse av hjerterytmeforstyrrelser. I denne forbindelse finner f.eks. azolderivater med formel (I) anvendelse. hvori. X, Y og Z er like eller forskjellige og betyr N eller CR2 ,. Ri kan ha flere betydninger og blant annet bety (C-C)-alkyl, (C3-C10 )-alkenyl eller (C-)-lkinyl,. Rkan ha flere betydninger og blant annet bety hydrogen, halogen, nltro, pentafluorfenyl eller cyano, A betyr en bifenylrest som eventuelt kan være sub-stituert, og. L betyr ((^-0)-alkandiyl og q er null eller 1.
NO932391A 1992-07-01 1993-06-30 Angiotensin-II-reseptorantagonister for behandling av hjerterytmeforstyrrelser NO932391L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4221536 1992-07-01
DE4228554 1992-08-27

Publications (2)

Publication Number Publication Date
NO932391D0 NO932391D0 (no) 1993-06-30
NO932391L true NO932391L (no) 1994-01-03

Family

ID=25916181

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932391A NO932391L (no) 1992-07-01 1993-06-30 Angiotensin-II-reseptorantagonister for behandling av hjerterytmeforstyrrelser

Country Status (6)

Country Link
US (1) US5468764A (no)
EP (1) EP0577023A3 (no)
JP (1) JPH0680629A (no)
AU (1) AU665694B2 (no)
CA (1) CA2099425A1 (no)
NO (1) NO932391L (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
AU6108596A (en) * 1995-06-15 1997-01-15 Merck & Co., Inc. Polymorphic forms of an angiotensin ii antagonist
US5693812A (en) * 1996-06-03 1997-12-02 Merck & Co. Inc. Polymorphic forms of an angiotensin II antagonist
JP3890453B2 (ja) * 1996-09-18 2007-03-07 リードケミカル株式会社 新規２，４−ジオキソピロリジンおよび２，４−ジオキソテトラヒドロフラン誘導体及び該化合物を有効成分とする医薬
JP2002504498A (ja) * 1998-02-25 2002-02-12 メルク エンド カムパニー インコーポレーテッド アンギオテンシンｉｉ受容体拮抗薬を用いてｑｔ分散を低下させる、または、ｑｔ分散の進行を阻害する方法
EE04904B1 (et) * 1998-07-15 2007-10-15 Teijin Limited Tiobensimidasooli derivaadid ja farmatseutiline kompositsioon
US20050267148A1 (en) * 1998-07-15 2005-12-01 Teijin Limited Benzimidazole derivative
ES2154191B1 (es) * 1998-11-24 2001-10-16 Ferrer Int Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos.
WO2001053272A1 (fr) * 2000-01-17 2001-07-26 Teijin Limited Inhibiteurs de chymase humaine
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443456A (en) * 1981-05-12 1984-04-17 William H. Rorer, Inc. Pyridyl alkylene amidinoureas
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5043447A (en) * 1987-04-24 1991-08-27 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
DE3911603A1 (de) * 1989-04-08 1990-10-18 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0400835A1 (en) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
EP0434038A1 (en) * 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
CA2041763A1 (en) * 1990-05-11 1991-11-12 Sheih-Shung T. Chen Microbial transformation process for antihypertensive products
US5210092A (en) * 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
WO1993018030A1 (en) * 1992-03-03 1993-09-16 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives as angiotensin ii antagonists
CA2075421A1 (en) * 1992-08-06 1994-02-07 Mikhail D. Mashkovsky Pharmaceutical preparation of antihypertensive, antianginal , antiarrhythmic and antiglaucomic action

Also Published As

Publication number Publication date
AU665694B2 (en) 1996-01-11
CA2099425A1 (en) 1994-01-02
EP0577023A2 (de) 1994-01-05
JPH0680629A (ja) 1994-03-22
US5468764A (en) 1995-11-21
NO932391D0 (no) 1993-06-30
EP0577023A3 (en) 1996-12-18
AU4163693A (en) 1994-01-06

Similar Documents

Publication Publication Date Title
NO932391L (no) Angiotensin-II-reseptorantagonister for behandling av hjerterytmeforstyrrelser
DK0681581T3 (da) Substituerede, kondenserede, pyrazolforbindelser og deres anvendelse som herbicider.
ES2114874T3 (es) Derivados de azol, procedimiento para su preparacion y su utilizacion.
DK0479903T3 (da) Substituerede imidazoler og deres anvendelse som angiotensin II hæmmere
NO20003231D0 (no) Inhibering av RAF-kinase ved anvendelse av aryl- og heteroarylsubstituerte heterosykliske ureaforbindelser
NO20010628L (no) Substituerte oksazol- og thiazolderivater som hPPAR <gamma> og hPPAR <alfa> aktivatorer
NO940261L (no) 5-leddete heterocykler, fremgangsmåte ved fremstilling derav og legemidler som inneholder disse forbindelser
NO872863L (no) AnalogifremgangsmŸte for fremstilling av terapeutiske imidazoler som blokkerer angiotensin-ii-reseptorer.
ATE214607T1 (de) Verwendung von aldosteronantagonisten zur hemmung von myocardfibrose
PL368109A1 (en) 2-iminopyrrolidine derivates
NO932390L (no) Antagonist-II-reseptorantagonister for behandling og profylakse av koronare hjertesykdommer
NO904799D0 (no) Substituerte n-(imidazolyl)alkylalanin-derivater.
EA199901096A1 (ru) Цианогуанидины в качестве ингибиторов пролиферации клеток
CA2292775A1 (en) Cyanoguanidines as cell proliferation inhibitors
FI955829A (fi) Heterosyklinen kemia
CO5540298A2 (es) Proceso para preparar un ligando de ppar de tiazol y polimorfos del mismo
FI906084A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 5-(2-metyyli-4,4,4-trifluoributyylikarbamoyyli)indolijohdannaisten valmistamiseksi
MX9703146A (es) Derivados de acido propenoico substituido con heterociclo como antagonistas de nmda.
NO980309L (no) Nye, anti-konvulsive imidazolin-2,4-dioner med en ortosubstituert ar(alk)yl-rest i 1-stilling, og deres fremstilling
NO20040981L (no) Fremgangsmate for fremstilling av 4-(imidazol-1-yl)benzensulfonamidderivater.
JPS5620516A (en) Remedy for edema, hypotension, cardiac insufficiency, and mucous congestion
TR200001365T2 (tr) Yeni heterosiklik ikame edilmiş a-hidroksikarbonik asit türevleri
RU97109468A (ru) Способ получения бис-1,2-(1,2,4-триазол-1-ил)этана
ES2057235T3 (es) Derivados de imidazol dicloro-sustituido como antifungales.
JPS5283887A (en) Heterocyclic compounds